EMCURE PHARMACEUTICALS L Share Price

EMCURE PHARMACEUTICALS L Share Price

NSE: EMCURE
|
Pharmaceuticals

₹ 1,863.70

-₹3.70 (-0.2%)
1D
Last updated 13 Oct, 2026, 15:29 IST

EMCURE PHARMACEUTICALS L Share Price Today

As of 14 Oct 2026, EMCURE PHARMACEUTICALS L share price is ₹1,863.70. The stock opened at ₹1,868.00, compared to its previous close of ₹1,867.40. During today's trading session, EMCURE PHARMACEUTICALS L share price moved in the range of ₹1,850.00 to ₹1,878.10, with an average price of ₹1,864.05 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,306.50 and a high of ₹2,100.70. On the performance front, EMCURE PHARMACEUTICALS L share price has increased by 14.61% over the last six months and is up 36.33% on a year-on-year basis.

₹1,850.00
0.20% down today
₹1,878.10
1D LOW
1D HIGH

EMCURE PHARMACEUTICALS L Returns Calculator

Volume
55,653
Average traded price
₹1,861.10
Last traded time
03:29:54 13 Oct
Last traded quantity
4
Circuit
L
H
₹1,680.70
₹2,054.10
52-week
L
H
₹1,306.50
₹2,100.70
Mkt Cap Cr
34,810.96
P/E
34.7
P/B
7.14
ROA
10.6%
ROE
18.67%
ROCE
21.76%
Quick Ratio
0.82
EV/EBITDA
18.42
Based on fundamentals, this stock's
Step 3 of 5
Performance
Neutral
Emcure Pharma performance is moderate compared to markets
Step 3 of 5
Valuation
Fairly Valued
Emcure Pharma appears to be fairly valued compared to its peers
Step 5 of 5
Earnings
Excellent
Emcure Pharma revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,22,067.0134.835.0511.19%13.74%17.33%2.3121.42
Divis Laboratories2,48,982.9885.1214.8514.6%15.32%19.56%3.556.28
Torrent Pharmaceuticals1,76,300.5082.5521.164.87%25.49%13.85%0.7538.11
Zydus Lifesciences1,13,615.6924.744.198.57%18.59%17.35%0.9114.87
Laurus Labs1,11,898.66102.6321.1110.38%16.77%16.14%0.6853.86
Cipla1,06,129.9631.623.087.92%11.27%14.95%2.517.83
Dr. Reddy's Laboratories1,02,707.4132.262.75.48%11.07%12.54%1.3515.86
Mankind Pharma99,089.5247.926.087.36%11.74%13.13%0.7425.7
Aurobindo Pharma97,972.4726.42.596.34%9.25%11.76%1.1512.47
Lupin89,628.8316.033.9614.47%23.76%24.88%1.429.56

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

About EMCURE PHARMACEUTICALS L

EMCURE PHARMACEUTICALS L Share Price
ISIN
INE168P01015
Sector Market Cap
₹ 34,810.96 Cr

Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.

EMCURE PHARMACEUTICALS L Financial Highlights

  • Revenue: EMCURE PHARMACEUTICALS L reported revenue of ₹9,216.20 crore in FY26 vs ₹7,963.26 crore in FY25. It showed an increase of 15.73% on a yearly basis.
  • Operating Profit: EMCURE PHARMACEUTICALS L reported an operating profit of ₹1,287.14 crore in FY26 vs ₹971.35 crore in FY25. It showed an increase of 32.51% on a year-on-year basis.
  • Net Profit: EMCURE PHARMACEUTICALS L reported a net profit of ₹941.27 crore in FY26 vs ₹707.47 crore in FY25. It showed an increase of 33.05% on a yearly basis.

EMCURE PHARMACEUTICALS L Quarterly Result Highlights

  • EMCURE PHARMACEUTICALS L reported revenue of ₹2,582.52 crore in Jun 2026, compared with ₹2,473.69 crore in Mar 2026, representing an increase of 4.40% on a quarter-on-quarter (QoQ) basis.
  • EMCURE PHARMACEUTICALS L reported an operating profit of ₹393.53 crore in Jun 2026, compared with ₹341.18 crore in Mar 2026, representing an increase of 15.34% on a quarter-on-quarter (QoQ) basis.
  • EMCURE PHARMACEUTICALS L reported a profit of ₹292.49 crore in Jun 2026, compared with ₹243.74 crore in Mar 2026, reflecting an increase of 20.00% on a QoQ basis.
  • The earnings per share (EPS) of EMCURE PHARMACEUTICALS L stood at ₹48.77 during Jun 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Know more
Promoters
77.83%
FII
4.88%
Other DII
1.60%
Retail and other
8.83%
Mutual funds
6.87%
Foreign Institutional Investor (FII)
FII shareholding by period
Sep 20253.29%
Dec 20253.59%
Mar 20263.35%
Jun 20264.88%
1 day
+0.06%
1 week
-2.80%
1 month
-5.57%
1 year
+36.33%
3 years
+37.48%
5 years
+37.48%
Day
Open / Close
Change %
13 Oct 26
₹1,868.00 / ₹1,863.70
-0.20%
12 Oct 26
₹1,828.10 / ₹1,867.40
+1.85%
09 Oct 26
₹1,864.70 / ₹1,833.50
-0.97%
08 Oct 26
₹1,905.10 / ₹1,851.50
-3.47%
Show more

EMCURE PHARMACEUTICALS L Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹9,203.54₹7,896.00₹6,658.25₹5,985.81
Other Income₹131.47₹72.79₹56.99₹45.91
Total Revenue₹9,335.01₹7,968.78₹6,715.24₹6,031.72
Total Expenses₹8,016.52₹6,987.06₹5,978.08₹5,278.36
Profit Before Tax₹1,287.14₹971.35₹727.23₹747.22
Tax₹345.87₹263.88₹199.65₹185.37
Profit After Tax₹941.27₹707.47₹527.58₹561.85
EPS - Basic₹48.77₹36.43₹27.54₹29.42
EPS - Diluted₹48.77₹36.43₹27.54₹29.42

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹1,287.14₹971.35₹727.23₹747.22
Income before WC changes₹1,841.76₹1,522.86₹1,270.38₹1,239.56
Change in Assets-₹913.59-₹599.85-₹166.98-₹277.81
Change in Liabilities₹383.45₹175.56₹217.49-₹14.42
Change in WC-₹530.13-₹424.30₹50.52-₹292.24
Cash flow from Operations₹943.55₹851.71₹1,097.24₹746.85
Cash flow from Investing-₹1,193.06-₹94.00-₹712.51-₹467.69
Cash flow from Financing₹343.43-₹813.96-₹164.21-₹145.40
Total Cash Flow₹93.92-₹56.25₹220.52₹133.77
Cash (Start of the year)-₹14.31₹43.99-₹174.53-₹308.17
Cash (End of the year)₹97.77-₹14.31₹43.99-₹174.53

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹4,000.38₹3,676.86₹3,546.25₹2,836.62
Current Assets₹5,612.10₹4,555.86₹4,259.92₹3,835.91
Total Assets₹9,612.48₹8,232.72₹7,806.16₹6,672.53
Current Liabilities₹3,912.24₹2,668.27₹3,210.47₹3,019.19
Net Current Asset₹1,699.86₹1,887.59₹1,049.44₹816.72
Non-Current Liabilities₹723.57₹922.90₹1,473.93₹1,003.68
Equity Capital₹4,976.67₹4,641.55₹3,121.77₹2,649.66
Total Equity & Liabilities₹9,612.48₹8,232.72₹7,806.16₹6,672.53

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹5,243.19₹4,381.92₹3,497.66₹3,107.09
Other Income₹311.66₹142.48₹138.26₹125.35
Total Revenue₹5,554.84₹4,524.40₹3,635.91₹3,232.44
Total Expenses₹4,585.58₹4,096.69₹3,426.69₹3,013.95
Profit Before Tax₹944.19₹427.71₹199.91₹212.34
Tax₹211.23₹110.58₹39.08₹52.28
Profit After Tax₹732.96₹317.13₹160.83₹160.06
EPS - Basic₹38.67₹16.95₹8.89₹8.85
EPS - Diluted₹38.67₹16.95₹8.89₹8.85

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹944.19₹427.71₹199.91₹212.34
Income before WC changes₹1,165.46₹711.85₹525.47₹521.55
Change in Assets-₹583.04-₹368.39-₹91.66-₹22.13
Change in Liabilities₹58.55₹280.94₹218.02₹90.49
Change in WC-₹524.49-₹87.45₹126.36₹68.37
Cash flow from Operations₹423.56₹558.29₹584.97₹505.37
Cash flow from Investing-₹948.10-₹435.61-₹171.08-₹270.44
Cash flow from Financing₹525.76-₹49.25-₹287.75-₹54.52
Total Cash Flow₹1.22₹73.43₹126.15₹180.42
Cash (Start of the year)-₹17.53-₹88.91-₹213.05-₹393.35
Cash (End of the year)-₹15.02-₹17.53-₹88.91-₹213.05

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹3,872.98₹2,956.06₹2,633.50₹2,456.44
Current Assets₹3,041.07₹2,460.05₹2,123.43₹2,159.41
Total Assets₹6,914.04₹5,416.11₹4,756.93₹4,615.85
Current Liabilities₹2,267.42₹1,719.16₹2,130.12₹1,996.33
Net Current Asset₹773.65₹740.89-₹6.68₹163.07
Non-Current Liabilities₹936.03₹672.59₹691.72₹777.65
Equity Capital₹3,710.60₹3,024.36₹1,935.10₹1,841.87
Total Equity & Liabilities₹6,914.04₹5,416.11₹4,756.93₹4,615.85
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
1868.6
1
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 1
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
6
Bullish
0
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
41.59
Neutral
ATR (14)
55.27
Neutral
STOCH(9,6)
30
Neutral
STOCH RSI (14)
29.79
Neutral
ADX(9)
22.16
Bearish
UO(9)
40.19
Neutral
ROC(12)
-5.77
Bearish
WillR(14)
-73.58
Neutral
Period
Simple value
Exponential vaue
5D
1878.56
1876.3
10D
1910.44
1899.66
20D
1939.52
1916.14
50D
1925.68
1905.84
100D
1859.52
1848.7
Volume trend — traded volume by day
13 Oct0L
12 Oct0L
9 Oct0L
8 Oct0L
7 Oct0L
Average0L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks
EMCURE PHARMACEUTICALS L Share Price
EMCURE PHARMACEUTICALS L
Pharmaceuticals
Add Stock
Add Another

EMCURE PHARMACEUTICALS L Share Price FAQs

Disclaimer: The information on this page, including prices, charts, financials, ratios, and other data, is provided for informational and educational purposes only. It is not investment advice, a research report, or a recommendation or solicitation to buy, sell, or hold any security. Data is sourced from third parties and exchanges, may be delayed, and is not guaranteed to be accurate, complete, or timely. Upstox is not liable for any loss arising from its use.